Evidence map›Paper›PMID 38957518›Full record

ArticleCureus2024

Heparin-Induced Hemorrhagic Bullous Dermatosis: A Rare Complication of Unfractionated Heparin.

Rida Zakar, Nader Saad, Marie El Tannoury, Boutros El Tannoury, Mohammad Ali Ismail, Moussa Riachy, Lamisse Karam

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rida ZakarMedical School, Université Saint Joseph, Beirut, LBN.
Nader SaadThoracic and Vascular Surgery, Hôtel-Dieu de France, Beirut, LBN.
Marie El TannouryPulmonary and Critical Care Medicine, Hôtel-Dieu de France, Beirut, LBN.
Boutros El TannouryOrthopaedic Surgery, Centre Hospitalier Universitaire Notre Dame Des Secours, Holy Spirit University of Kaslik, Kaslik, LBN.
Mohammad Ali IsmailAnesthesia and Critical Care, Hôtel-Dieu de France, Beirut, LBN.
Moussa RiachyPulmonary and Critical Care Medicine, Hôtel-Dieu de France, Beirut, LBN.
Lamisse KaramThoracic and Vascular Surgery, Hôtel-Dieu de France, Beirut, LBN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a case of an 82-year-old female with a significant medical history of hypertension and Alzheimer's disease who developed heparin-induced hemorrhagic bullous dermatosis during treatment for a subsegmental pulmonary embolism. The patient was admitted with lower extremity edema and cyanosis, diagnosed with a subsegmental pulmonary embolism, and started on therapeutic doses of unfractionated heparin. On the sixth day of heparin therapy, she developed abdominal bloating and a diffuse exanthematous rash, which progressed to hemorrhagic bullae on the plantar and dorsal aspects of her feet, alongside extensive purpura on her legs. Laboratory findings revealed thrombocytopenia. Multidisciplinary consultations confirmed the diagnosis of heparin-induced hemorrhagic bullous dermatosis. Management included continuing unfractionated heparin with close monitoring, supportive topical treatments, and a subsequent transition to rivaroxaban. The patient's condition improved significantly, and she was discharged in stable condition. This case highlights the importance of recognizing rare adverse reactions to heparin and raises the question of preventive measures or risk factors related to this manifestation.

Indexed as

bullous haemorrhagic dermatosisdeep vein thrombosis (dvt)heparin administrationnon-fractioned heparinpulmonary embolism (pe)

Identifiers

PMID38957518
PMCPMC11219031

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.